Merus N.V.
Merus N.V. (MRUS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MRUS · as of Jun 8, 2026
Key Statistics
Explore Merus N.V. Data
mrus stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 22 · Buy rate: 45.5%
The MRUS analyst consensus is Hold, based on ratings from 22 Wall Street analysts over the past 3 months. The average 12-month price target is $88.69, representing -1.46% downside from the current price of $90.00.
Competitors & Peers
mrus competitorsMRUS
ABVX
AXSM
CORT
CYTK
HALOStock Performance
Full HistoryAbout Merus N.V.
Merus N.V. a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includ…
what is merus n.v. · mrus stock overview · merus n.v. company profile · who is merus n.v. ceo · mrus NASDAQ · merus n.v. headquarters · merus n.v. business segments
About Stock Overview & Key Data
Merus N.V. (MRUS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 19, 2016. As of the latest trading session, MRUS stock price is $90.00, with a market capitalization of $6.8B. The stock has returned +127.22% over the past 12 months and +0.00% year-to-date.
According to 22 Wall Street analysts, the consensus rating for Merus N.V. stock is Hold, with an average 12-month price target of $88.69. In fiscal year 2024, Merus N.V. reported revenue of $34.9M and net income of -$207.9M. For detailed data — including Merus N.V. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Merus N.V. (MRUS) stock price is $90.00. The stock is traded on NASDAQ under the ticker symbol MRUS. The 52-week range is $33.19 – $97.14.